Collin founded Kolosis in 2019 and has served as CEO since its inception. With over 20 years of experience in medical devices, biomaterials, and regenerative biologics, Collin has successfully led high-performance teams in orthobiologics marketing, U.S. sales, and international markets across large, growth-stage, and start-up organizations.

Before founding Kolosis, Collin held leadership roles in spine and orthobiologics at NuVasive and Orthofix for over 12 years. At Orthofix, he directed the biologics sales organization across 24 Western states, expanding distribution channels, strengthening hospital and GPO relationships, and driving sales to over $50 million with the Trinity Elite cellular allograft product. At NuVasive, he led global expansion efforts, establishing international strategies and leadership structures, before managing marketing for a $100 million+ biologics portfolio, supporting the growth of Osteocel Plus/Pro cellular allograft products and launching the AttraX advanced biosynthetic graft.

Collin began his device career at Cook Medical, where he served as the first President and Representative Director of Cook Japan, building its sales, marketing, regulatory, and quality functions. He also simultaneously led the Asia Pacific and Latin America regions as Strategic Business Unit Leader for Peripheral Intervention, driving expansion and overseeing operations in Japan, India, China, and Korea.

Collin holds a bachelor’s degree in international politics from Brigham Young University and a law degree from Indiana University, Bloomington.